L. Bedenne

发表

Impact of neoadjuvant chemoradiation on lymph node status in esophageal cancer: post hoc analysis of a randomized controlled trial.

J. Bosset, C. Mariette, J. Triboulet, 2015, Annals of surgery.

Oesophageal cancer: exploring controversies overview of experts’ opinions of Austria, Germany, France, Netherlands and Switzerland

T. Ruhstaller, C. Mariette, J. V. van Lanschot, 2015, Radiation oncology.

Estimating the cost related to surveillance of colorectal cancer in a French population

M. Abrahamowicz, C. Lejeune, C. Bonithon-Kopp, 2009, The European Journal of Health Economics.

Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Bernard Leduc, Franck Bonnetain, Olivier Bouché, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

T. Conroy, Y. Bécouarn, O. Bouché, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial.

T. Conroy, M. Ducreux, O. Bouché, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study.

B. Chauffert, J. Bosset, P. Maingon, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer

T. Conroy, Y. Bécouarn, O. Bouché, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial

J. Taieb, L. Bedenne, P. Puig, 2008, Expert review of anticancer therapy.

Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial.

T. Conroy, E. Van Cutsem, B. Nordlinger, 2005, The Lancet. Oncology.

[Postoperative follow-up in patients with colorectal cancers who have undergone curative resection: intensive or conventional follow-up?].

J. Seitz, B. Sastre, L. Dahan, 2008, Gastroenterologie clinique et biologique.

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.

P. Rougier, O. Bouché, A. de Gramont, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02).

I. Sobhani, O. Bouché, P. Michel, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomised Trial Comparing Three Different Schedules of Infusional 5FU and Raltitrexed Alone as First-Line Therapy in Metastatic Colorectal Cancer

J. Pignon, M. Ducreux, A. Dunant, 2006, Oncology.

Cost-Effectiveness Analysis of First-Line Chemotherapies in Metastatic Colorectal Cancer

J. Pignon, M. Ducreux, O. Bouché, 2007, Oncology.

PRODIGE 34-FFCD 1402-ADAGE: Adjuvant chemotherapy in elderly patients with resected stage III colon cancer: A randomized phase 3 trial.

F. Retornaz, J. Seitz, T. André, 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Toxicity of Oxaliplatin Plus Fluorouracil/Leucovorin Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer: A Population-Based Study

C. Lepage, J. Faivre, A. Bouvier, 2014, Annals of Surgical Oncology.

Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials.

R. Labianca, V. Torri, E. Van Cutsem, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

How do gastroenterologists follow patients with colorectal cancer after curative surgical resection? A three-year population-based study.

C. Lejeune, C. Bonithon-Kopp, R. Coriat, 2007, Gastroenterologie clinique et biologique.

High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study

M. Loriot, P. Rougier, O. Bouché, 2015, Molecular Cancer Therapeutics.

Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.

J. Bosset, B. Nordlinger, P. Rougier, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Greil, B. Chauffert, S. Barni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Which patients with colorectal cancer are followed up by general practitioners? A population-based study

C. Lejeune, C. Bonithon-Kopp, S. Béjean, 2007, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre

M. Ychou, P. Rougier, R. Guimbaud, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: results from the multicenter, randomised trial Fédération Francophone de Cancérologie Digestive 9601.

J. Pignon, M. Ducreux, V. Boige, 2013, European journal of cancer.

Participation in mass screening for colorectal cancer: results of screening and rescreening from the Burgundy study.

J. Faivre, P. Arveux, L. Bedenne, 1991, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Epidemiological evidence for distinguishing subsites of colorectal cancer.

J. Faivre, P. Arveux, L. Bedenne, 1989, Journal of epidemiology and community health.

Biliary tract cancers in Cote-d'Or (France): incidence and natural history.

J. Faivre, P. Hillon, L. Bedenne, 1987, Journal of epidemiology and community health.

Correction

J. Faivre, P. Hillon, L. Bedenne, 1987 .

Idarubicin‐loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial

B. Chauffert, C. Lepage, A. Denys, 2014, Alimentary pharmacology & therapeutics.

First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control

C. Mariette, G. Piessen, A. Kramar, 2016, Oncology.

Les cancers digestifs

J. Faivre, A. Bouvier, L. Bedenne, 2008 .

Management and prognosis of esophageal cancers: has progress been made?

J. Faivre, A. Bouvier, C. Binquet, 2006, European journal of cancer.

Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000–05): Preliminary results

M. Ducreux, P. Rougier, O. Bouché, 2007 .

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results

O. Bouché, F. Retornaz, J. Taieb, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Management of colorectal polyps: Is all the effort worthwhile?

C. Williams, L. Bedenne, 1990, Journal of gastroenterology and hepatology.

[Descriptive epidemiology of cancer of the pancreas].

J. Faivre, P. Arveux, L. Bedenne, 1990, Bulletin du cancer.

Views of a general population on mass screening for colorectal cancer: the Burgundy Study.

J. Faivre, P. Arveux, L. Bedenne, 1992, Preventive medicine.

Small bowel adenocarcinoma: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).

M. Pocard, Y. Bécouarn, O. Bouché, 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.

J. Bosset, C. Mariette, J. Triboulet, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08)

H. Hawle, T. Ruhstaller, M. Montemurro, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Pilot Study of Transarterial Chemoembolization With Pirarubicin and Amiodarone for Unresectable Hepatocellular Carcinoma

B. Chauffert, J. Cercueil, R. Loffroy, 2009, American journal of clinical oncology.

Editorial: IDASPHERE phase I trial for chemoembolisation for HCC ‐ authors' reply: a necessary step for treatment optimisation and standardisation

B. Guiu, L. Bedenne, M. Boulin, 2014, Alimentary pharmacology & therapeutics.

Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710.

P. Rougier, J. Raoul, J. Seitz, 2009, Endocrine-related cancer.

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.

O. Bouché, F. Retornaz, J. Taieb, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Metastatic Gastrointestinal Cancer: Safety of Cisplatin Combined with Continuous 5-FU Versus Bolus 5-FU and Leucovorin (Methodology)

M. Ychou, J. Duffour, M. Ducreux, 2008 .

VINORELBINE IN EPIDERMOID ESOPHAGEAL

T. Conroy, M. Glabbeke, J. Seitz, 2018 .

Intergroup phase III trial of neo-adjuvant chemotherapy, followed by chemoradiation and surgery with and without cetuximab in locally advanced esophageal carcinoma: First results from the SAKK 75/08 trial.

H. Hawle, T. Ruhstaller, C. Mariette, 2017 .

Folinic acid modulated bolus 5-FU or infusional 5-FU for adjuvant treatment of patients of UICC stage III colon cancer: Preliminary analysis of the PETACC-2-study.

A. Carrato, C. Köhne, P. Rougier, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].

B. Chauffert, P. Maingon, P. Rougier, 2011, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Primary prophylactic granulocyte colony-stimulating factor (GCSF) in Gilbert’s disease patients treated with FOLFIRI first line for metastatic colorectal cancer (mCRC): Final results of the FFCD 0604 study.

M. Loriot, P. Laurent-Puig, C. Lepage, 2013 .

[Survival in colorectal cancers in population statistics].

J. Faivre, L. Bedenne, M. Boutron, 1986, Sozial- und Praventivmedizin.

Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: Analysis of a randomized controlled phase III trial FFCD 9901.

C. Mariette, V. Boige, D. Pezet, 2010 .

3030 POSTER Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000–05): preliminary results

M. Ducreux, P. Rougier, O. Bouché, 2007 .

Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial).

M. Ychou, J. Duffour, M. Ducreux, 2006, Anticancer research.

Patterns of recurrence in early‐stage oesophageal cancer after chemoradiotherapy and surgery compared with surgery alone

C. Mariette, J. Triboulet, F. Mornex, 2015, The British journal of surgery.

702 Randomized phase III trial comparing 5FU bolus and low dose leucovorin versus 5FU bolus plus continuous 5FU infusion and high dose LV in metastatic colorectal cancer

P. Rougier, O. Bouché, L. Bedenne, 1995 .

Phase III preliminary results of preoperative fluorouracil (F) and cisplatin (P) versus surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC 94012-FFCD 9703 trial.

J. Pignon, T. Conroy, M. Ychou, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Cisplatin, 5-FU and preoperative radiotherapy in esophageal epidermoid cancer. Multicenter phase II FFCD 8804 study].

T. Conroy, J. Faivre, J. Seitz, 1998, Gastroenterologie clinique et biologique.

Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice.

B. Chauffert, E. Solary, H. Pelletier, 1990, British Journal of Cancer.

An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma

X. Paoletti, J. Cercueil, F. Bonnetain, 2016, BMJ Open.

High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn’s Disease

J. Hugot, B. Bonaz, J. Rey, 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Endoscopic ultrasonography is an independent predictive factor of prognosis in locally advanced esophageal cancer. Results from the randomized FFCD 9102 study from the Fédération Francophone de Cancérologie Digestive.

T. Conroy, D. Arsène, O. Bouché, 2008, Gastroenterologie clinique et biologique.

Is it still time for meta-analyses in operable esophageal cancers, or rather for a change of paradigm?

K. Le Malicot, L. Bedenne, A. Drouillard, 2017, Journal of thoracic disease.

Is surgery always necessary in esophageal cancer?

J. Vincent, J. Jouve, L. Bedenne, 2011, Esophagus.

Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.

J. Pignon, T. Conroy, M. Ychou, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preoperative Chemoradiotherapy (CT-RT) Improves Local Control in T3-4 Rectal Cancers: Results of the FFCD 9203 Randomized Trial

T. Conroy, O. Bouché, P. Romestaing, 2005 .

Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial.

J. Douillard, V. Boige, O. Bouché, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gastric Adenocarcinoma in Familial Adenomatous Polyposis Can Occur Without Previous Lesions

L. Faivre, S. Olschwang, P. Rat, 2014, Journal of Gastrointestinal Cancer.

[Cancer of the esophagus in the department of Côte-d'Or].

J. Faivre, P. Hillon, L. Bedenne, 1986, Bulletin du cancer.

Prognosis of hepatocellular carcinoma (HCC): Comparison of four staging systems in two French clinical trials

X. Paoletti, P. Rougier, O. Bouché, 2007 .

Multicenter randomized phase III trial comparing tamoxifen alone or with transarterial lipiodol chemoembolization (TLC) for unresectable hepatocellular carcinoma (HCC) in cirrhotic patients

O. Bouché, F. Bonnetain, L. Bedenne, 2005 .

Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)

B. Chauffert, M. Ychou, P. Rougier, 2010, Gut.

Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.

O. Bouché, A. Bedjaoui, F. Retornaz, 2018, European journal of cancer.

Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma

B. Chauffert, J. Cercueil, F. Ghiringhelli, 2011, Anti-cancer drugs.

A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer.

T. Conroy, P. Arveux, C. Mariette, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Increased cytotoxicity and stability of Lipiodol-pirarubicin emulsion compared to classical doxorubicin-Lipiodol: potential advantage for chemoembolization of unresectable hepatocellular carcinoma

B. Chauffert, J. Cercueil, P. Fauré, 2001, Anti-cancer drugs.

Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma.

P. Rougier, V. Boige, O. Bouché, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

O-0028 Adjuvant Folfox4 +/- Cetuximab in KRAS Wild-Type Patients with Resected Stage III Colon Cancer Results from the Petacc8 Intergroup Trial

L. Collette, P. Laurent-Puig, J. Tabernero, 2012 .

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.

L. Collette, R. Salazar, P. Laurent-Puig, 2014, The Lancet. Oncology.

A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).

T. Conroy, M. Ychou, M. Ducreux, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials.

X. Paoletti, P. Rougier, O. Bouché, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinicopathological aspects of the neuropathy of neurogastrointestinal encephalomyopathy (MNGIE) in four patients including two with a Charcot–Marie–Tooth presentation

C. Lacroix, B. Messing, C. Matuchansky, 2005, Journal of Neurology.

Early surgery for failure after chemoradiation in operable thoracic oesophageal cancer. Analysis of the non-randomised patients in FFCD 9102 phase III trial: Chemoradiation followed by surgery versus chemoradiation alone.

T. Conroy, C. Mariette, O. Bouché, 2015, European journal of cancer.

Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study.

B. Chauffert, J. Bosset, P. Rougier, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial.

Pierre Michel, Bernard Denis, Pierre-Luc Etienne, 2011, The Lancet. Oncology.

Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).

T. Conroy, J. Bosset, O. Bouché, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma.

M. Ychou, P. Rougier, F. Bonnetain, 2010, European journal of cancer.

Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402).

X. Causse, P. Rougier, F. Caroli-Bosc, 2008, European journal of cancer.

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.

T. Conroy, J. Douillard, V. Boige, 2014, The Lancet. Oncology.

Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer.

L. Collette, T. Conroy, M. Namer, 1997, European journal of cancer.

High dose rate brachytherapy for superficial cancer of the esophagus.

I. Barillot, J. Horiot, P. Maingon, 2000, International journal of radiation oncology, biology, physics.

Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.

T. Conroy, P. Arveux, C. Mariette, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

T. Conroy, C. Bascoul-Mollevi, J. Douillard, 2017, European journal of cancer.

Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials

X. Paoletti, P. Rougier, S. Collette, 2008, Quality of Life Research.

VINORELBINE IN EPIDERMOID ESOPHAGEAL CARCINOMA 167

T. Conroy, J. Seitz, A. Adenis, 2017 .

Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.

M. van Glabbeke, T. Conroy, M. Glabbeke, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hepatic arterial infusion of cisplatin diluted in hypotonic 25 g/l glucose solution administered in balloon-occluded hepatic artery: experimental rationale and clinical pilot study.

B. Chauffert, P. Fargeot, N. Isambert, 2001, Journal of experimental & clinical cancer research : CR.

Adjuvant Folfox4 with or without Cetuximab (CTX) in Patients (PTS) with Resected Stage III Colon Cancer (CC): Dfs and OS Results and Subgroup Analyses of the PETACC8 Intergroup Phase III Trial

L. Collette, P. Laurent-Puig, C. Lepage, 2012 .

Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803.

D. Arsène, P. Rougier, B. Buecher, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial

J. Pignon, T. Conroy, M. Ychou, 2007 .

Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).

R. Labianca, L. Collette, A. Carrato, 2008, European journal of cancer.

Adenoma‐carcinoma sequence or “de novo” Carcinogenesis?. A study of adenomatous remnants in a population‐based series of large bowel cancers

J. Faivre, P. Hillon, L. Bedenne, 1992, Cancer.

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

P. Couzigou, M. Ducreux, C. Borel, 2018, European journal of cancer.

Phase III trial of protracted compared with split-course chemoradiation for esophageal carcinoma: Federation Francophone de Cancerologie Digestive 9102.

P. Maingon, F. Bonnetain, X. Mirabel, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801).

M. Ychou, B. Nordlinger, M. Ducreux, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Incidence and Patterns of Late Recurrences in Rectal Cancer Patients

V. Bouvier, G. Launoy, V. Jooste, 2015, Annals of Surgical Oncology.

Adjuvant treatments for gastric cancer: from practice guidelines to clinical practice.

C. Lepage, J. Faivre, P. Maingon, 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Trends in the incidence and management of biliary tract cancer: a French population-based study.

C. Lepage, J. Faivre, A. Bouvier, 2011, Journal of hepatology.

[Digestive cancers: the new frontier of hepatogastroenterology].

J. Faivre, A. Bouvier, L. Bedenne, 2003, Gastroenterologie clinique et biologique.

Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.

C. Lombard-Bohas, O. Bouché, F. Bonnetain, 2009, European journal of cancer.

Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology.

T. Conroy, P. Rougier, P. Arveux, 2005, Gastroenterologie clinique et biologique.

Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child–Pugh B cirrhosis

C. Lepage, G. Deplanque, V. Bourcier, 2021, Hepatology International.

Concurrent concentrated chemoradiation therapy in squamous cell carcinoma of the esophagus: long term results of a national multicenter phase II study in 122 inoperable patients (FFCD 8803)

T. Conroy, J. Seitz, F. Dumas, 2000 .

[Appendectomy, cholecystectomy, cholelithiasis and colorectal cancer. A retrospective case control study at the Côte-d'Or].

J. Faivre, P. Arveux, L. Bedenne, 1991, Gastroenterologie clinique et biologique.

Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma.

F. Bonnetain, O. Hentic, B. Landi, 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Patterns of Surveillance Practices After Curative Surgery for Colorectal Cancer in a French Population

C. Lejeune, A. Bouvier, C. Binquet, 2005, Diseases of the colon and rectum.

P h ase I I T rial o f Vinorelbine i n M e tastatic Squam o us C ell E sophageal C arcinoma

T. Conroy, J. Seitz, A. Adenis, 1996 .

Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists

F. Bonnetain, L. Bedenne, N. Methy, 2010, BMC Cancer.

A phase III randomised trial of LV 5 FU 2 1 irinotecan versus LV 5 FU 2 alone in adjuvant high-risk colon cancer ( FNCLCC Accord 02 / FFCD 9802 )

T. Conroy, M. Ychou, M. Ducreux, 2009 .

A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colon Cancer 2 study.

A. Carrato, C. Köhne, P. Reichardt, 2013, European journal of cancer.

Factors influencing inclusion in digestive cancer clinical trials: A population-based study.

V. Jooste, I. Fournel, A. Bouvier, 2015, Digestive and Liver Disease.

Outcome of the nonrandomized patients in the FFCD 9102 trial: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus

T. Conroy, C. Mariette, O. Bouché, 2008 .

Oesophageal cancer: exploring controversies overview of experts’ opinions of Austria, Germany, France, Netherlands and Switzerland

T. Ruhstaller, C. Mariette, J. V. van Lanschot, 2015, Radiation oncology.

Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma.

J. Cercueil, C. Lepage, B. Guiu, 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting.

X. Paoletti, P. Rougier, C. Lombard-Bohas, 2011, Journal of hepatology.

[Cost of a mass screening program for colorectal cancer using the occult blood test].

J. Faivre, P. Arveux, L. Bedenne, 1992, Gastroenterologie clinique et biologique.

[Preliminary results of a mass screening program for colorectal cancer].

J. Faivre, P. Arveux, L. Bedenne, 1990, Gastroenterologie clinique et biologique.

Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer.

F. Guillemin, T. Conroy, J. Faivre, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

USE OF A DECISION ANALYSIS MODEL TO ASSESS THE COST-EFFECTIVENESS OF FDG PET IMAGING IN THE MANAGEMENT OF METACHRONOUS LIVER METASTASES OF COLORECTAL CANCER

F. Guillemin, T. Conroy, J. Faivre, 2005 .

[Cancers of the rectum and colon in the Côte-d'Or department: treatment, prognosis].

J. Faivre, P. Hillon, L. Bedenne, 1985, Gastroenterologie clinique et biologique.

Primary liver cancer in Côte d'Or (France).

J. Faivre, P. Hillon, L. Bedenne, 1988, International Journal of Epidemiology.

Patterns of care and outcomes in oesophageal cancer.

V. Jooste, J. Faivre, A. Bouvier, 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Epidemiology, management, and prognosis of malignant large bowel polyps within a defined population.

J. Faivre, P. Arveux, P. Hillon, 1992, Gut.

131I thyroid uptake in patients treated with 131I-Lipiodol for hepatocellular carcinoma

J. Cercueil, C. Touzery, F. Brunotte, 2001, European Journal of Nuclear Medicine.

Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801).

M. Ychou, B. Nordlinger, M. Ducreux, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.

E. Baudin, C. Lepage, P. Rougier, 2017, European journal of cancer.

Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma.

B. Chauffert, J. Cercueil, C. Lepage, 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

46 Randomized phase II trial of LV5FU2, LV5FU2-cisplatinum or LV5FU2-irinotecan in patients (pts) with metastatic gastric or cardial adenocarcinoma (MGA): final results of study FFCD 9803

D. Arsène, O. Bouché, J. Raoul, 2003 .

[Concurrent concentrated radio-chemotherapy of epidermoid cancer of the esophagus. Long-term results of a phase II national multicenter trial in 122 non-operable patients (FFCD 8803)].

T. Conroy, J. Seitz, F. Dumas, 2000, Gastroenterologie clinique et biologique.

Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer: The FFCD PRODIGE 13 randomised phase III trial.

C. Lepage, O. Bouché, D. Pezet, 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Quels changements dans le Thsaurus National de Cancrologie Digestive en 2005

M. Ducreux, P. Rougier, D. Peiffert, 2006 .

FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802).

V. Boige, O. Bouché, F. Ghiringhelli, 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02).

I. Sobhani, O. Bouché, P. Michel, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

J. Pignon, V. Boige, D. Malka, 2013, European journal of cancer.

[Cronkhite-Canada syndrome and arsenic poisoning: fortuitous association or new etiological hypothesis?].

F. Boschi, E. Justrabo, L. Bedenne, 1999, Gastroenterologie clinique et biologique.

Idarubicin‐loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial

J. Cercueil, B. Guiu, P. Hillon, 2014, Alimentary pharmacology & therapeutics.

A. Carrato, C. Köhne, P. Reichardt, 2013, European journal of cancer.

PRODIGE 20: Bevacizumab + chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC)--A randomized phase II trial.

O. Bouché, F. Retornaz, J. Taieb, 2015 .